Testing HLX43 plus Serplulimab for advanced solid tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have advanced or metastatic cancer that has not improved with standard treatments, or you have a specific type of lung cancer (NSCLC) with an EGFR mutation.
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- You need to provide a sample of your tumor tissue to test for a protein called PD-L1.
- You should be in fairly good health (able to do daily activities without help) and have no major heart, lung, or immune system problems.
- You cannot have had a serious reaction to immunotherapy before, or have active brain metastases, infections, or other cancers in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This trial tests a new combination of two immunotherapy drugs (HLX07 and serplulimab) plus chemotherapy versus standard treatments (pembrolizumab or serplulimab plus chemo) for people with advanced squamous non-small cell lung cancer who haven't had treatment yet. The goal is to see if the new combination works better.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.